Replicor Inc.
292 million people have chronic hepatitis B. We're developing the cure.
292 million people have chronic hepatitis B. We're developing the cure.
Replicor Inc. is a Canadian biotechnology company dedicated to developing a cure for chronic hepatitis B (HBV) and delta (HDV) infections. Their innovative nucleic acid polymer (NAP) technology directly targets the immunosuppressive protein (HBsAg) responsible for chronic HBV infection and liver disease. Their lead clinical NAP drug product, REP 2139-Mg, has shown promising results in restoring immune control of HBV infection in 78% of patients and eliminating HDV infection in 74% of patients. What's particularly noteworthy is that these effects persist without any therapy, allowing the liver to heal. Moreover, their REP 2139-Mg based combination therapy is poised to revolutionize the treatment of chronic HBV and HDV infections and aligns with the WHO's goal of eliminating viral hepatitis by 2030. With 292 million people suffering from chronic hepatitis B, Replicor's work could potentially have a significant global impact.
There is no investment information
No recent news or press coverage available for Replicor Inc..
We care about your data, and we'd love to use cookies make your experience better.
